This accredited digital CME program integrates contemporary precision oncology workflows for RET-altered cancers, covering end-to-end biomarker testing, MDT coordination, and evidence-based use of selective RET inhibitors across non–small cell lung cancer (NSCLC) and thyroid cancers, with embedded case studies and practical pearls aligned to current guidelines and late-breaking data.